Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunity.

Laboratory investigation; a journal of technical methods and pathology - 1 Feb 2017

Bresler Scott C, Min Le, Rodig Scott J, Walls Andrew C, Xu Shuyun, Geng Songmei, Hodi F Stephen, Murphy George F, Lian Christine G

Abstract excerpt

Ipilimumab (IPI) is a monoclonal antibody that targets the inhibitory CTLA4 receptor of T cells, enhancing T-cell-driven antitumor responses. IPI therapy in metastatic melanoma results in significant improvement in disease-free and overall survival, although after initial responses disease progression generally ensues. Identification of specific responses in tissue where melanoma tumor cells are subjected to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autoimmunity
Share to CTLA-4 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Inhibitor of Apoptosis Proteins

Share to Ipilimumab

Share to Neoplasm Metastasis

Share to Protein-Tyrosine Kinases

Share to Skin Neoplasms

Share to Survivin

Source

Identifiers

PMID: 27918555
DOI: 10.1038/labinvest.2016.126

Genes

CTLA4
TTK
CDK1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunity.PMID 27918555Read ↗

Checkpoint-blocker induced autoimmunity is associated with pretreatment T cell expression profiles and favourable outcome in melanomaSemantic proximity Read ↗

Systematic evaluation of the predictive gene expression signatures of immune checkpoint inhibitors in metastatic melanomaSemantic proximity Read ↗

A four-gene signature predicts survival and anti-CTLA4 immunotherapeutic responses based on immune classification of melanomaSemantic proximity Read ↗

Integrating tumor and immune cell transcriptomics to predict immune checkpoint inhibitor primary resistance in metastatic cutaneous melanomaSemantic proximity Read ↗

Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid TumorsSemantic proximity Read ↗

Transcriptional analysis of immune modulatory genes in melanoma treated with PD-1 blockadeSemantic proximity Read ↗

Multiomics analysis reveals a Type III driven immune response in immunotherapy-induced toxicity in melanoma and identifies potential new therapeutic targetsSemantic proximity Read ↗

Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma.Semantic proximity Read ↗

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.Semantic proximity Read ↗

Decitabine reverses innate immune gene suppression in rare melanomasSemantic proximity Read ↗

Clinical Impact of Immune Checkpoint Inhibitor (ICI) Response, DNA Damage Repair (DDR) Gene Mutations and Immune-Cell Infiltration in Metastatic Melanoma Subtypes.Semantic proximity Read ↗

Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.